REGENERON PHARMACEUTICALS, INC. (REGN) Operating cash flow 2016–2025
REGENERON PHARMACEUTICALS, INC. (REGN) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$5.0BFY2025 · since FY2016: $1.5B → $5.0B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $5.0B | +12.6% |
| FY2024 | $4.4B | -3.8% |
| FY2023 | $4.6B | -8.4% |
| FY2022 | $5.0B | -29.2% |
| FY2021 | $7.1B | +170.5% |
| FY2020 | $2.6B | +7.7% |
| FY2019 | $2.4B | +10.7% |
| FY2018 | $2.2B | +67.9% |
| FY2017 | $1.3B | -12.0% |
| FY2016 | $1.5B | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More REGN financial trends
REGN RevenueREGN Net incomeREGN Net marginREGN Gross profitREGN Gross marginREGN Operating incomeREGN Operating marginREGN Free cash flowREGN Capital expendituresREGN Return on equityREGN Stock buybacksREGN Dividends paidREGN Total assetsREGN Total liabilitiesREGN Shareholders’ equityREGN overview →